Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men and women between the ages of 30 and 80 who have been diagnosed with a heart condition caused by ATTR amyloid (a protein that builds up in the heart) and are experiencing symptoms of heart failure.
- You must have evidence of heart failure, which means at least one of the following: a hospital stay in the past 12 months related to heart failure; a blood test result showing elevated heart-stress markers (BNP or NT-proBNP) in the past 12 months; or a formal diagnosis of heart failure from your doctor.
- You must have already been diagnosed with ATTR cardiac amyloidosis, either through a tissue biopsy with special staining and testing, or through a bone scan without abnormal protein findings in the blood.
- Genetic testing of the TTR gene must have already been done or be in progress to confirm your specific type of the condition.
- Participants will be grouped based on whether they are starting an approved TTR-stabilizing medication (such as tafamidis) within 5 days of joining the trial, or whether they are already currently taking one of these medications.
Who may not be able to join:
- People who have another known cause of heart muscle disease other than ATTR amyloidosis.
- People who have been diagnosed with a different type of amyloidosis affecting the heart, called light-chain (AL) cardiac amyloidosis.
- People who have had a heart transplant.
- People who have had a liver transplant.
- People who have taken certain amyloidosis medications recently — specifically patisiran in the past 90 days, inotersen in the past 180 days, or vutrisiran at any point in the past — or who are currently enrolled in another clinical trial for ATTR treatments.
- People whose kidneys are not functioning well enough, based on a specific blood test measuring kidney filtration rate (confirm with trial site if unsure about your kidney test results).
- People who are expected to have any breaks in their ATTR cardiac amyloidosis treatment lasting 3 months or more after joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Justin Grodin, MD MPH, University of Texas Southwestern Medical Center
Phone: 214-645-7303
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Serial blood levels of circulating TTR amyloid aggregates (TAAs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.